Abstract
Objective
Patients with pathologic N2 non-small cell lung cancer comprise a heterogeneous group. The objective of this study was to evaluate which subgroup of patients with pathologic N2 benefit from surgery in terms of survival probability.
Methods
This retrospective study included 141 patients who had undergone major resection with pathologically proven N2 from 1990 to 2006 (103 with adenocarcinoma, 38 with squamous cell carcinoma). Patients undergoing preoperative induction therapy were excluded. Records were examined for age, gender, tumor size, surgical procedure, surgical side, clinical N status, primary tumor lobe, curative resection, and metastatic N2 stations.
Results
In patients with adenocarcinoma, surgical procedure, clinical N status, curative resection, and metastatic N2 stations were significant prognostic factors in univariate analysis. Age and curative resection were significant factors in patients with squamous cell carcinoma. In multivariate analysis, clinical N2 (P = 0.003), incomplete resection (P = 0.04), and multi-station N2 (P = 0.004) were significant adverse prognostic factors in patients with adenocarcinoma, whereas only incomplete resection (P = 0.002) was significant in patients with squamous cell carcinoma. For adenocarcinoma patients with pathologic N2, the 5-year survival rates were 58.8% for clinical N0-1 and single-station N2, 50% for clinical N2 and single-station N2, 23.9% for clinical N0-1 and multi-station N2, and 0% for clinical N2 and multi-station N2.
Conclusions
Prognosis of patients with pathologic N2 can be grouped according to clinical N status and metastatic N2 stations in adenocarcinoma, but not in squamous cell carcinoma. Only adenocarcinoma patients with pathologic N2 appear to have heterogeneous subgroups with different prognoses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andre F, Grunenwald D, Pignon JP et al (2000) Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. JCO 18:2981–2989
Detterbeck FC, Boffa DJ, Tanoue LT (2009) The new lung cancer staging system. Chest 136:260–271
Goldstraw P, Mannam GC, Kaplan DK et al (1994) Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 107:19–28
Ichinose Y, Kato H, Koike T et al (2001) Completely resected stage IIIA non–small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg 122:803–808
Inoue M, Sawabata N, Takeda S et al (2004) Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg 127:1100–1106
Keller SM, Vangel MG, Wagner H et al (2004) Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg 128:130–137
Misthos P, Sepsas E, Athanassiadi K et al (2004) Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg 25:502–508
Misthos P, Sepsas E, Kokotsakis J et al (2008) The significance of one-station N2 disease in the prognosis of patients with non small-cell lung cancer. Ann Thorac Surg 86:1626–1631
Ratto GB, Costa R, Maineri P et al (2009) Is there a subset of patients with preoperatively diagnosed N2 non–small cell lung cancer who might benefit from surgical resection? J Thorac Cardiovasc Surg 138:849–858
Robinson LA, Ruckdeschel JC, Wagner RH Jr et al (2007) Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:243S–265S
Rusch VW, Asamura H, Watanabe H et al (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568–577
Sakao Y, Okumura S, Mun M et al (2010) Prognostic heterogeneity in multilevel N2 non-small cell lung cancer patients: importance of lymphadenopathy and occult intrapulmonary metastases. Ann Thorac Surg 89:1060–1063
Silvestri GA, Gould MK, Margolis ML et al (2007) Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132:178S–201S
Suzuki K, Nagai K, Yoshida J et al (1999) The prognosis of surgically resected N2 non-small cell lung cancer. J Thorac Cardiovasc Surg 118:145–153
Vansteenkiste JF, De Leyn PR, Deneffe GJ et al (1997) Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 63:1441–1450
Conflict of interest
None declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Funakoshi, Y., Takeuchi, Y., Kusumoto, H. et al. Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery?. J Cancer Res Clin Oncol 138, 1027–1033 (2012). https://doi.org/10.1007/s00432-012-1175-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1175-5